Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use XOLREMDI™ safely and effectively. See full prescribing information for XOLREMDI ®. XOLREMDI ®(mavorixafor) capsules, for oral use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes.
- generic_name
- mavorixafor
- product_names
- mavorixafor
- ndc
- 83296-100, 83296-100-60, 83296-100-90, 83296-100-12
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en